Sema4 and OPKO Health Inc. announced they have signed a definitive agreement for Sema4 to acquire OPKO's wholly owned subsidiary, GeneDx Inc. In conjunction with the Transaction, Jason Ryan, a member of Sema4's Board of Directors, former CFO of Foundation Medicine and most recently Chief Operating and Financial Officer of Magenta Therapeutics will assume the role of Executive Chair of Sema4's Board of Directors. Mr. Ryan succeeds Joshua Ruch, who will continue to serve on Sema4's Board of Directors as the Chairperson of its Compensation Committee.